![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, Florida (Z.C., K.N.B., J.W.); and Bristol-Myers Squibb Oncology, Princeton, New Jersey (F.Y.L.)
Received October 20, 2005; accepted January 24, 2006
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
tyrosine kinase activity in vitro by BMS-354825 was observed at 4 nM. Direct comparison of BMS-354825 and another PDGFR inhibitor, imatinib (Gleevec, STI571), in VSMCs indicated that BMS-354825 is 67-fold more potent than imatinib in inhibition of PDGFR activation. BMS-354825 also inhibited Src tyrosine kinase in A10 cells. At the cell level, PDGF stimulated migration and proliferation of A10 cells and human AoSMCs, both of which were inhibited by BMS-354825 in a concentration dependent manner in the low nanomolar range. These results suggest that BMS-354825 is a potent inhibitor of PDGF-stimulated VSMC activities and a potential agent for the development of a new therapy for vascular obstructive diseases such as restenosis.
; Michaels and Chatterjee, 2002). Therefore, restenosis represents a major problem limiting the long-term efficacy of these revascularization therapies. Moreover, after coronary artery bypass surgery, narrowing (stenosis) of the transplanted artery can also occur that necessitates further medical treatments.
Abnormal migration and proliferation of VSMCs are critical events in the pathogenesis of artery obstructive diseases such as restenosis (Bailey, 2002; Sanz-Gonzalez et al., 2004; Levitzki, 2005). Although several growth factors and cytokines are involved in the development of restenosis, many lines of evidence have indicated that PDGF plays a prominent role in the pathogenesis of restenosis. PDGF is the most potent mitogen and motogen for VSMCs (Heldin and Westermark, 1999). PDGF is present at sites of vascular injury from activated platelets, monocytes, and cells of the artery wall (Raines, 2004). Expression of exogenous PDGF in animal arteries can induce intimal thickening through stimulation of VSMC proliferation and migration and synthesis of extracellular matrix (Pompili et al., 1995). It is noteworthy that inhibition of PDGF as well as PDGFR by immunological, molecular biological, and pharmacological methods can suppress development of restenotic lesions in animal models (Ferns et al., 1991; Sirois et al., 1997; Myllarniemi et al., 1999; Levitzki, 2005).
Imatinib (Gleevec, STI571, CGP57148B) is the first protein tyrosine kinase inhibitor that has been successfully developed into a targeted therapy drug. It is currently used to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumor based on inhibition of Bcr-Abl and c-Kit protein tyrosine kinases, respectively (Logrono et al., 2004; Deininger et al., 2005). Besides Bcr-Abl and c-Kit, imatinib also inhibits PDGFR tyrosine kinase (Buchdunger et al., 1996; Druker et al., 1996). Experiments in animals have shown that imatinib inhibits restenosis after balloon angio-plasty and stenosis after allograft (Myllarniemi et al., 1999; Sihvola et al., 2003). Inhibition of PDGFR by imatinib, however, requires micromolar concentrations in cell-based assays (Buchdunger et al., 1996; Sanz-Gonzalez et al., 2004).
After the findings by us and others that a Src tyrosine kinase inhibitor, PD180970, and other pyrido[2,3-d]pyrimidine derivatives could cross-inhibit Bcr-Abl (Dorsey et al., 2000; Wisniewski et al., 2002; Huron et al., 2003), several dual Src/Bcr-Abl inhibitors are now being developed as new therapeutic agents for CML. One of these is the orally bio-available BMS-354825 (Lombardo et al., 2004; Shah et al., 2004; Burgess et al., 2005; O'Hare et al., 2005), which is currently in clinical trials in CML patients. Because the Bcr-Abl tyrosine kinase inhibitor imatinib was originally identified in the screening of PDGFR tyrosine kinase inhibitors, we sought to determine whether BMS-354825 could also cross-inhibit PDGFR in VSMCs and suppress PDGF-stimulated migration and proliferation of VSMCs. We provide evidence here that BMS-354825 is a potent PDGFR tyrosine kinase inhibitor in VSMCs and that it inhibits cellular responses to PDGF in VSMCs at low nanomolar concentrations. These results reveal BMS-354825 as a potential agent for development of a new therapy for restenosis and stenosis, which will help to improve the long-term success of angioplasty/stenting and coronary bypass surgery.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
was from Upstate Biotechnology (Lake Placid, NY). Antibodies to PDGFR and Src were from Calbiochem (San Diego, CA). Antibodies to Akt, STAT3, Erk1/2, Src (for immunoblotting), insulin-like growth factor-1 receptor (IGF-1R), and epidermal growth factor receptor (EGFR) were from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-activated Erk1/2 antibody was from Promega (Madison, WI). PDGF-BB was from PeproTech (Rocky Hill, NJ). Propidium iodide and rat tail type I collagen were from Roche (Indianapolis, IN). BMS-354825 (N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate) was provided by Bristol-Myers Squibb. Imatinib (Gleevec, STI571) was provided by Novartis (Basel, Switzerland). Cell Culture. The A10 rat aortic smooth muscle cell line was obtained from American Type Culture Collection (Manassas, VA) and grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin and 100 µg/ml streptomycin. Primary culture of human aortic smooth muscle cells (AoSMCs) was obtained from Cambrex Bio Science Walkersville, Inc. (Walkersville, MD) and grown in SmGM-2 Bulletkit medium (Cambrex) plus 100 units/ml penicillin and 100 µg/ml streptomycin. Human AoSMCs were used before the 7th passage. Cells were maintained at 37°C in a humidified 95% air and 5% CO2 incubator.
Immunoprecipitation and Immunoblotting. Cells were lysed in ice-cold lysis buffer (25 mM Tris-HCl, pH 7.2, 150 mM NaCl, 25 mM NaF, 1 mM benzamidine, 1% Triton X-100, 1 mM Na3VO4, 20 mM p-nitrophenyl phosphate, 2 µg/ml leupeptin, 2 µg/ml aprotinin, and 100 µg/ml phenylmethylsulfonyl fluoride). Cell lysate supernatants were obtained by microcentrifugation at 4°C for 15 min and the protein concentration was determined. For immunoblotting analysis of cell lysates, cell lysate supernatants were heat-denatured in SDS loading buffer. Antibodies to activated STAT3, activated Akt, activated Erk1/2, and phosphotyrosine were used to assess the activation of these molecules and receptor tyrosine kinases by immunoblotting. Immunoblotting was performed essentially as described previously (Cunnick et al., 2001, 2002; Ren and Wu, 2003) using the SuperSignal West Pico chemiluminescent reagent (Pierce, Rockford, IL). Each immunoprecipitation was performed using 600 µg of cell lysate supernatant, 2 µg of specific antibody indicated in the figure legends, and 30 µl of Protein-A or Protein-G at 4°C for 2 h. Immune complex was collected by microcentrifugation and washed three times with the lysis buffer. Quantification of immunoreactive band intensity was achieved using the ImageQuant program (GE Healthcare, Little Chalfont, Buckinghamshire, UK).
Protein Tyrosine Kinase Assays. PDGFR was immunoprecipitated with an anti-PDGFR antibody (Calbiochem). Immunoprecipitates were washed twice with the lysis buffer and twice with kinase buffer (50 mM HEPES, pH 7.4, 10 mM MnCl2, and 0.1 mM Na3VO4). The immune complex kinase assay was performed in a 50-µl reaction mixture (kinase buffer plus 20 µCi of [
-32P]ATP, and 10 µM ATP) at 30°C for 15 min. Kinase reaction was terminated by addition of 17 µl of 4x SDS loading buffer and heat-denaturation at 95°C for 10 min. Samples were subjected to 8% SDF-polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane. Phosphorylation was quantified by filmless autoradiographic analysis or autoradiography. The immune complex kinase assay for c-Src was performed as described previously (Ren et al., 2004).
Cell Migration Assay. Cell migration was measured using the Transwell cell migration assay (Ren et al., 2004). Transwell cell culture insert polycarbonate membrane (6.5 mm, 8.0-µm pore size; Costar, Corning, NY) was coated with rat tail type I collagen (10 µg/ml in PBS) at 4°C for 18 h and air-dried. VSMCs (80% confluent) were serum-starved in DMEM/0.1% BSA for 18 h, detached from plates by digestion with 1:3 diluted trypsin-EDTA (Invitrogen), washed with DMEM, and resuspended in DMEM/0.1% BSA at 5 x 104 cells/ml for A10 cells or 2.5 x 104 cells/ml for human AoSMCs. Cell suspension (0.2 ml per well) was incubated with BMS-354825 or solvent (DMSO) in 1.5-ml microcentrifuge tube for 20 min before been placed in the upper chamber of Transwell. The lower chamber contained 0.6 ml of DMEM/0.1% BSA with or without 5 ng/ml PDGF-BB (PeproTech) and BMS-354825. After incubation at 37°C/5% CO2 for 4 h, cells remaining on the upper membrane surface were mechanically removed with a cotton swab. Migrated cells on the lower side of membrane were fixed and stained with the HEMA3 reagents (Fisher Scientific, Swanee, GA) and enumerated under a microscope in eight randomly chosen fields with a 10 x 10 lens. Each field for quantification of the migrated cell number has an area of 0.8 x 0.6 mm.
Cell Proliferation Analysis. A10 cells and human AoSMC cells were seeded in triplicate at 2 x 104 per plate in 6-cm plates in DMEM/1% FBS with or without PDGF-BB (10 ng/ml). After 24 h (day 0), cells were treated with DMSO (solvent) or 10 to 50 nM BMS-354825. Medium was changed on day 3. Viable cell number was determined on day 6 as described previously (Dorsey et al., 2000). For the recovery experiment, cells were treated as above for 6 days and then cultured without BMS-354825 for another 6 days.
|
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
, STAT3, Akt, and Erk2 by immunoblotting analyses (Fig. 1A). PDGFR is the predominant PDGFR subunit in VSMCs (Raines, 2004) and the only functional PDGFR subunit in A10 cells (Rao et al., 1997). STAT3, Akt, and Erk2 signaling pathways have been reported to mediate PDGF-induced cell migration and proliferation in VSMCs (Graf et al., 1997; Shibata et al., 2003; Zhan et al., 2003; Neeli et al., 2004; Kim et al., 2005; Vantler et al., 2005). PDGF treatment markedly increased PDGFR tyrosine phosphorylation, which was detectable at the earliest time point examined (1 min). BMS-354825 (50 nM) effectively blocked PDGF-stimulated PDGFR tyrosine phosphorylation at all time points examined. Figure 1A also shows that STAT3, Akt, and Erk2 were activated by PDGF in A10 cells as measured by activation-specific phosphorylation and these were inhibited by BMS-354825.
We next immunoprecipitated PDGFR from A10 cells that had been treated with PDGF-BB (5 ng/ml, 5 min) in the presence of 0 to 25 nM BMS-354825 and then analyzed the PDGFR tyrosine phosphorylation by immunoblotting. As illustrated in Fig. 1B, tyrosine phosphorylation of PDGFR was induced by PDGF stimulation in A10 cells; the response was inhibited by BMS-354825 with an IC50 of 3 nM in this assay.
To confirm that BMS-354825 inhibits PDGFR tyrosine kinase activity, PDGFR was immunoprecipitated from A10 cells with or without prior PDGF stimulation (5 ng/ml, 5 min). The PDGFR tyrosine kinase activity was determined in vitro in the immune complexes by autophosphorylation in the presence of various concentrations of BMS-354825. As shown in Fig. 1C, BMS-354825 inhibited PDGFR tyrosine kinase activity in a concentration-dependent manner. The 50% inhibition of PDGFR phosphorylation was observed at 4 nM BMS-354825.
Comparison of PDGFR Inhibition by BMS-354825 and Imatinib. In addition to inhibiting Bcr-Abl and c-Kit, imatinib also inhibits PDGFR tyrosine kinase. To compare the inhibition of PDGFR in VSMCs by BMS-354825 and imatinib, A10 cells were preincubated with various concentrations of BMS-354825 or imatinib, stimulated with PDGF-BB, and activation of PDGFR, STAT3, Akt, and Erk2 were analyzed. Figure 2A shows that PDGF-stimulated PDGFR tyrosine phosphorylation was completely blocked by 50 nM BMS-354825. In contrast, 5 µM imatinib was required to achieve the same level of PDGFR inhibition in parallel experiments. Likewise, complete inhibition of PDGF-stimulated Akt and Erk2 activation were observed in cells treated with 50 nM BMS-354825 but only with 5 µM imatinib, whereas decrease in STAT3 tyrosine phosphorylation appeared at lower concentrations of imatinib (Fig. 2A). It is noteworthy that inhibition of Akt by both BMS-354825 and imatinib was observed only at the highest drug concentration tested; PDGFR is a strong activator of the phosphoinositide-3 kinase signaling pathway because it binds phosphoinositide-3 kinase directly. Comparison of 50% inhibition of PDGFR tyrosine phosphorylation by BMS-354825 and imatinib in these experiments indicated that BMS-354825 was 67-fold more potent than imatinib in inhibiting PDGFR tyrosine phosphorylation (Fig. 2B).
|
|
The primary culture of human AoSMCs seemed to have an elevated level of active STAT3 in the absence of PDGF stimulation (Fig. 3). Nevertheless, STAT3 was further activated by PDGF, which was blocked by BMS-354825. BMS-354825, however, was unable to reduce the active STAT3 to a level below the basal activation state in human AoSMCs. Complete inhibition of PDGF-stimulated Akt and Erk2 activation was achieved at 50 nM BMS-354825 in human AoSMCs (Fig. 3), which is similar to data obtained in A10 cells (Fig. 2).
Inhibition of c-Src Tyrosine Kinase by BMS-354825 in VSMCs. To determine whether BMS-354825 inhibits c-Src activity in VSMCs, c-Src was immunoprecipitated from serum-starved A10 cells treated with PDGF-BB (5 ng/ml) for 0 to 30 min in the presence or absence of 50 nM BMS-354825, and the Src tyrosine activity was determined by an immune complex kinase assay using a GST fusion protein of Gab1 fragment as an exogenous substrate (Ren et al., 2004). c-Src isolated from A10 cells without exposure to BMS-354825 and PDGF had detectable kinase activity (Fig. 4A). This kinase activity was reduced to a residual level in c-Src isolated from BMS-354825-treated cells (Fig. 4A). PDGF treatment did not lead to a detectable increase in c-Src kinase activity in A10 cells in repeated experiments. Nevertheless, as in unstimulated cells, the activity of c-Src tyrosine kinase in PDGF-stimulated A10 cells was suppressed by BMS-354825 to the residual level (Fig. 4A). This result indicated that c-Src was basally active in A10 cells and that BMS-354825 effectively inhibited the c-Src kinase activity in these cells.
|
IGF-1R and EGFR in A10 Cells Are Not Sensitive to BMS-354825 Inhibition. Besides PDGFR, A10 cells also express IGF-1R and EGFR. To assess whether BMS-354825 inhibits other receptor tyrosine kinases in VSMCs, we examined the effects of BMS-354825 on these two receptor tyrosine kinases in A10 cells. As shown in Fig. 5, IGF-1 induced IGF-1R tyrosine phosphorylation, whereas EGF induced EGFR tyrosine phosphorylation in A10 cells. No detectable inhibition of IGF-1R and EGFR tyrosine phosphorylation was observed when A10 cells were treated with up to 50 nM BMS-354825. These data are consistent with a previous report that the IC50s for inhibition of IGF-1R and EGFR by BMS-354825 in the in vitro kinase assays were >5 µM and 180 nM, respectively (Lombardo et al., 2004).
|
|
The primary human AoSMCs had a higher basal migration activity, which is 4 times that of A10 cells. In the presence of PDGF (5 ng/ml), migration of human AoSMCs was increased 3-fold. Again, PDGF-stimulated human AoSMC cell migration was inhibited by BMS-354825 (Fig. 6C).
Inhibition of VSMC Proliferation by BMS-354825. To determine the effect of BMS-354825 on PDGF-stimulated VSMC proliferation, rat A10 cells were incubated in medium containing low serum (1% FBS), PDGF (10 ng/ml), and/or 0 to 50 nM BMS-354825 for 6 days and viable cell numbers were determined. As shown in Fig. 7A, A10 cell proliferation was stimulated 5-fold by PDGF. BMS-354825 effectively inhibited PDGF-stimulated A10 cell proliferation. Complete inhibition was achieved at 50 nM BMS-354825. Similar results were obtained in human AoSMCs (Fig. 7B).
|
A previous study showed that the PDGFR specific tyrosine kinase inhibitor AG-1295 could inhibit porcine SMC proliferation, and the effect was reversible and not toxic (Banai et al., 1998). To evaluate whether the inhibitory effect of BMS-354825 on A10 cell proliferation is reversible, two sets of A10 cells were treated with 0 to 50 nM BMS-354825 for 6 days. After this time, BMS-354825 was removed from one set of cells and cells were cultured for another 6 days. Viable cell numbers were determined on day 12. As shown in Fig. 7D, A10 cells proliferation resumed after BMS-354825 withdrawal. Thus, the inhibitory effect of BMS-354825 on A10 cell proliferation was reversible, suggesting that BMS-354825 does not exert a cytotoxic effect on these cells.
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
; Bowman et al., 2001). However, biochemical evidence suggests that inhibition of PDGFR plays a major role in suppression of PDGF-stimulated responses in VSMCs by BMS-354825.
First, our data show that BMS-354825 is a potent inhibitor of PDGFR. The IC50 for inhibition of PDGFR tyrosine kinase in PDGF-stimulated A10 cells is 3 nM. A similar IC50 (4 nM) was obtained in the in vitro kinase assay. While this work was in progress, Lombardo et al. (2004) reported the kinase selectivity profile of BMS-354825, which showed that BMS-354825 inhibited PDGFR in vitro with an IC50 of 28 nM. Although Lombardo et al. (2004) performed no cell-based assay in their study, our data and theirs are consistent in demonstrating that BMS-354825 is a potent PDGFR inhibitor in vitro. The slight difference in IC50 for inhibition of PDGFR may reflect different assay conditions used to determine the PDGFR kinase activity between these two studies.
We found that Src is basally active in A10 cells and that BMS-354825 inhibits the basal Src activity (IC50 = 2 nM). Src kinase activity may be essential for cellular activities such as migration (Heldin and Westermark, 1999). Thus, blocking Src activity could contribute to the overall effect of BMS-354825 in inhibition of PDGF-stimulated VSMC migration. However, we did not detect measurable PDGF-induced Src activation in A10 cells, whereas marked activation of PDGFR was readily detectable. Thus, Src kinase activity alone is insufficient to account for the higher migratory activity of VSMCs observed in the presence of PDGF. Furthermore, although imatinib has no Src tyrosine kinase inhibitor activity (Druker et al., 1996), it suppressed the PDGF-stimulated activation of PDGFR, STAT3, Akt, and Erk2 in A10 cells. Therefore, inhibition of the PDGFR tyrosine kinase activity alone could have major effects on blocking PDGF-stimulated responses in VSMCs.
Several studies have shown that PDGFR inhibitors such as imatinib and AG-1295 are effective in suppressing restenosis and stenosis in experimental animals (Myllarniemi et al., 1999; Fishbein et al., 2000; Sihvola et al., 2003; Levitzki, 2005). Inhibition of PDGFR in VSMCs by imatinib and AG-1295 requires micromolar concentrations (Fishbein et al., 2000; Sanz-Gonzalez et al., 2004). In contrast, near-complete inhibition of PDGFR activation and PDGF-stimulated activities in VSMCs was observed with 50 nM BMS-354825 in this study. Direct comparison of BMS-354825 and imatinib in A10 cells indicates that BMS-354825 is 67-fold more potent that imatinib (Fig. 2). Thus, BMS-354825 is a much more potent PDGFR inhibitor than imatinib.
Inhibition of PDGF-stimulated VSMC proliferation by BMS-354825 is reversible. It has been reported that the vascular endothelial growth factor receptor is not sensitive to BMS-354825 inhibition (Lombardo et al., 2004). These observations suggest that BMS-354825 is unlikely to cause unmanageable damage to the vascular system. In support of this notion, imatinib, which also inhibits PDGFR, does not cause an adverse effect in the cardiovascular system in CML patients who have been treated with the drug for more than 4 years (Lahaye et al., 2005). The reversibility of the inhibitory effect of PDGF-stimulated VSMC proliferation by BMS-354825 also raises the question of whether BMS-354825 will be effective in suppressing restenosis. It is possible that restenosis-promoting activities peak shortly after vascular injury and lessen afterward. Therefore, one would predict that VSMC proliferation is not likely to resume when BMS-354825 is terminated after sufficient period of treatment unless there is new vascular injury.
BMS-354825 is currently being developed as an anticancer drug. We demonstrated here that it is very effective in inhibiting PDGF-stimulated VSMC migration and proliferation. VSMC migration and proliferation are critical events in the development of restenosis, which is a major problem for the long-term efficacy of the widely performed angioplasty and stenting procedures for coronary artery disease. Thus, in addition to being a promising anticancer drug, BMS-354825 is a potential novel therapeutic agent for cardiovascular diseases involving abnormal VSMC activities such as restenosis and stenosis.
|
Footnotes |
|---|
ABBREVIATIONS: VSMC, vascular smooth muscle cell; PDGF, platelet-derived growth factor; CML, chronic myeloid leukemia; PDGFR, platelet-derived growth factor receptor; STAT, signal transducer and activator of transcription; Erk, extracellular signal-regulated kinase; IGF-1R, insulin-like growth factor-1 receptor; EGFR, epidermal growth factor receptor; BMS-354825, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; AoSMC, aortic smooth muscle cell; PBS, phosphate-buffered saline; BSA, bovine serum albumin; DMSO, dimethyl sulfoxide; SMC, smooth muscle cells; AG-1295, 6,7-dimethyl-2-phenylquinoxaline; PD180970, 6-(2,6-dichloro-phenyl)-2-(4-fluoro-3-methylphenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one.
Address correspondence to: Dr. Jie Wu, Molecular Oncology Program, SRB-3, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612. E-mail: wu{at}moffitt.usf.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Banai S, Wolf Y, Golomb G, Pearle A, Waltenberger J, Fishbein I, Schneider A, Gazit A, Perez L, Huber R, et al. (1998) PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 97: 1960-1969.
Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, and Jove R (2001) Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 98: 7319-7324.
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, and Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-104.
Burgess MR, Skaggs BJ, Shah NP, Lee FY, and Sawyers CL (2005) Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 102: 3395-3400.
Cunnick JM, Mei L, Doupnik CA, and Wu J (2001) Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2. J Biol Chem 276: 24380-24387.
Cunnick JM, Meng S, Ren Y, Desponts C, Wang HG, Djeu JY, and Wu J (2002) Regulation of the mitogen-activated protein kinase signaling pathway by SHP2. J Biol Chem 277: 9498-9504.
Dangas G and Kuepper F (2002) Cardiology patient page. Restenosis: repeat narrowing of a coronary artery: prevention and treatment. Circulation 105: 2586-2587.
Deininger M, Buchdunger E, and Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653.
Dorsey JF, Jove R, Kraker AJ, and Wu J (2000) The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 60: 3127-3131.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, and Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566.[CrossRef][Medline]
Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, and Ross R (1991) Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science (Wash DC) 253: 1129-1132.
Fishbein I, Waltenberger J, Banai S, Rabinovich L, Chorny M, Levitzki A, Gazit A, Huber R, Mayr U, Gertz SD, et al. (2000) Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler Thromb Vasc Biol 20: 667-676.
Graf K, Xi XP, Yang D, Fleck E, Hsueh WA, and Law RE (1997) Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 29: 334-339.
Heldin CH and Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316.
Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, and Moasser MM (2003) A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res 9: 1267-1273.
Kim JH, Jin YR, Park BS, Kim TJ, Kim SY, Lim Y, Hong JT, Yoo HS, and Yun YP (2005) Luteolin prevents PDGF-BB-induced proliferation of vascular smooth muscle cells by inhibition of PDGF beta-receptor phosphorylation. Biochem Pharmacol 69: 1715-1721.[CrossRef][Medline]
Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, et al. (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103: 1659-1669.[CrossRef][Medline]
Levitzki A (2005) PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc Res 65: 581-586.
Logrono R, Jones DV, Faruqi S, and Bhutani MS (2004) Recent advances in cell biology, diagnosis and therapy of gastrointestinal stromal tumor (GIST). Cancer Biol Ther 3: 251-258.[Medline]
Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al. (2004) Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658-6661.[CrossRef][Medline]
Michaels AD and Chatterjee K (2002) Cardiology patient pages. Angioplasty versus bypass surgery for coronary artery disease. Circulation 106: e187-e190.
Myllarniemi M, Frosen J, Calderon Ramirez LG, Buchdunger E, Lemstrom K, and Hayry P (1999) Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc Drugs Ther 13: 159-168.[CrossRef][Medline]
Neeli I, Liu Z, Dronadula N, Ma ZA, and Rao GN (2004) An essential role of the Jak-2/STAT-3/cytosolic phospholipase A2 axis in platelet-derived growth factor BB-induced vascular smooth muscle cell motility. J Biol Chem 279: 46122-46128.
O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, et al. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65: 4500-4505.
Pompili VJ, Gordon D, San H, Yang Z, Muller DW, Nabel GJ, and Nabel EG (1995) Expression and function of a recombinant PDGF B gene in porcine arteries. Arterioscler Thromb Vasc Biol 15: 2254-2264.
Raines EW (2004) PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15: 237-254.[CrossRef][Medline]
Rao RS, Miano JM, Olson EN, and Seidel CL (1997) The A10 cell line: a model for neonatal, neointimal, or differentiated vascular smooth muscle cells? Cardiovasc Res 36: 118-126.
Ren Y, Meng S, Mei L, Zhao ZJ, Jove R, and Wu J (2004) Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J Biol Chem 279: 8497-8505.
Ren Y and Wu J (2003) Simultaneous suppression of Erk and Akt/PKB activation by a Gab1 pleckstrin homology (PH) domain decoy. Anticancer Res 23: 3231-3236.[Medline]
Sanz-Gonzalez SM, Castro C, Perez P, and Andres V (2004) Role of E2F and ERK1/2 in STI571-mediated smooth muscle cell growth arrest and cyclin A transcriptional repression. Biochem Biophys Res Commun 317: 972-979.[CrossRef][Medline]
Shah NP, Tran C, Lee FY, Chen P, Norris D, and Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (Wash DC) 305: 399-401.
Shibata R, Kai H, Seki Y, Kato S, Wada Y, Hanakawa Y, Hashimoto K, Yoshimura A, and Imaizumi T (2003) Inhibition of STAT3 prevents neointima formation by inhibiting proliferation and promoting apoptosis of neointimal smooth muscle cells. Hum Gene Ther 14: 601-610.[CrossRef][Medline]
Sihvola RK, Tikkanen JM, Krebs R, Aaltola EM, Buchdunger E, Laitinen O, Koskinen PK, and Lemstrom KB (2003) Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits. Transplantation 75: 334-339.[CrossRef][Medline]
Sirois MG, Simons M, and Edelman ER (1997) Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening. Circulation 95: 669-676.
Vantler M, Caglayan E, Zimmermann WH, Baumer AT, and Rosenkranz S (2005) Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells. Only phosphatidylinositol 3'-kinase is important. J Biol Chem 280: 14168-14176.
Wang YZ, Wharton W, Garcia R, Kraker A, Jove R, and Pledger WJ (2000) Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity. Oncogene 19: 2075-2085.[CrossRef][Medline]
Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, et al. (2002) Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 62: 4244-4255.
Zhan Y, Kim S, Izumi Y, Izumiya Y, Nakao T, Miyazaki H, and Iwao H (2003) Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration and gene expression. Arterioscler Thromb Vasc Biol 23: 795-801.
This article has been cited by other articles:
|
|
 |
|
  Y. Yang, R. Rao, J. Shen, Y. Tang, W. Fiskus, J. Nechtman, P. Atadja, and K. Bhalla Role of Acetylation and Extracellular Location of Heat Shock Protein 90{alpha} in Tumor Cell Invasion Cancer Res., June 15, 2008; 68(12): 4833 - 4842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Groenman, M. Rutter, J. Wang, I. Caniggia, D. Tibboel, and M. Post Effect of chemical stabilizers of hypoxia-inducible factors on early lung development Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L557 - L567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Shor, E. A. Keschman, F. Y. Lee, C. Muro-Cacho, G. D. Letson, J. C. Trent, W. J. Pledger, and R. Jove Dasatinib Inhibits Migration and Invasion in Diverse Human Sarcoma Cell Lines and Induces Apoptosis in Bone Sarcoma Cells Dependent on Src Kinase for Survival Cancer Res., March 15, 2007; 67(6): 2800 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. AGGARWAL, G. SETHI, K. S. AHN, S. K. SANDUR, M. K. PANDEY, A. B. KUNNUMAKKARA, B. SUNG, and H. ICHIKAWA Targeting Signal-Transducer-and-Activator-of-Transcription-3 for Prevention and Therapy of Cancer: Modern Target but Ancient Solution Ann. N.Y. Acad. Sci., December 1, 2006; 1091(1): 151 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Puttini, A. M. L. Coluccia, F. Boschelli, L. Cleris, E. Marchesi, A. Donella-Deana, S. Ahmed, S. Redaelli, R. Piazza, V. Magistroni, et al. In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells Cancer Res., December 1, 2006; 66(23): 11314 - 11322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Fiskus, M. Pranpat, M. Balasis, P. Bali, V. Estrella, S. Kumaraswamy, R. Rao, K. Rocha, B. Herger, F. Lee, et al. Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate-Sensitive or Imatinib Mesylate-Resistant Chronic Myelogenous Leukemia Cells. Clin. Cancer Res., October 1, 2006; 12(19): 5869 - 5878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Lyle and K. K. Griendling Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology, August 1, 2006; 21: 269 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhang and K. E. Meier New Assignments for Multitasking Signal Transduction Inhibitors Mol. Pharmacol., May 1, 2006; 69(5): 1510 - 1512. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
